Peloton Therapeutics Doses First Patient with Solid Tumors with Follow-On Hypoxia-Inducible Factor 2α (HIF-2α) Antagonist

December 15, 2016, 8:00 AM Central Standard Time

DALLAS,TX  –  Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing novel small molecule cancer therapies, announced today dosing of the first patient with their follow-on small molecule drug targeting Hypoxia-Inducible Factor 2a (HIF-2a), PT2977. The clinical trial is designed to assess the safety and pharmacokinetics of PT2977 in patients with a variety of solid tumors.  For more information on the clinical trial of PT2977 visit https://clinicaltrials.gov/ct2/show/NCT02974738?term=peloton+therapeutics&rank=1.

About Peloton Therapeutics

Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops novel small molecule cancer therapies targeting unexploited molecular vulnerabilities. Peloton Therapeutics’ lead program, PT2385, is a first-in-class small molecule targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other cancers. To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.

Peloton Contact:

John A. Josey, Ph.D.

Chief Executive Officer

Phone: +1 (972) 629-4100

 

Media Contact:

Mike Beyer

Sam Brown Inc.

Phone: +1 (312) 961-2502

mikebeyer@sambrown.com